Fast-Tracking Biosimilars Approval Process

This guide discusses the fast-tracking of biosimilars approval and the factors contributing to the growth of the global biosimilars market. It outlines the totality-of-evidence framework as defined by the FDA, which emphasizes the integration of various types of studies to justify regulatory approval. The framework relies on analytical comparisons between biosimilars and reference products to establish molecular similarity. The document explains that an abbreviated clinical program can suffice if the biosimilar is shown to be highly similar to the reference medicine. It also details the complexities involved in demonstrating biosimilarity, including the need for comprehensive analytical techniques and a risk-based approach to assess quality attributes. The summary concludes with the importance of aligning these processes with FDA guidelines to streamline submissions to regulatory agencies.